|
|
| Product Name: | FK-614 | | Synonyms: | FK-614;3-[(2,4-DICHLOROPHENYL)METHYL]-2-METHYL-N-PENTYLSULFONYLBENZIMIDAZOLE-5-CARBOXAMIDE;1H-Benzimidazole-6-carboxamide, 1-[(2,4-dichlorophenyl)methyl]-2-methyl-N-(pentylsulfonyl)-;ATx-08001;ATx-08-001 | | CAS: | 193012-35-0 | | MF: | C21H23Cl2N3O3S | | MW: | 468.4 | | EINECS: | | | Product Categories: | | | Mol File: | 193012-35-0.mol |  |
| | FK-614 Chemical Properties |
| density | 1.37±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 100 mg/mL (213.49 mM; Need ultrasonic) | | form | Solid | | pka | 2.53±0.40(Predicted) | | color | White to off-white |
| | FK-614 Usage And Synthesis |
| Uses | FK 614 is a novel non-thiazolidinedione (TZD) peroxisome proliferator-activated receptor (PPAR) γ agonist, that ameliorates insulin resistance in Zucker fatty rats. | | in vivo | FK614 (0.32~3.2 mg/kg; p.o.; 14 days) dose-dependently reduces plasma glucose level[3].
FK614 (0.1~10 mg/kg; p.o.; 14 days) improves the impaired glucose tolerance[3]. | Animal Model: | db/db Mice | | Dosage: | 0.1~10 mg/kg | | Administration: | P.o. | | Result: | Improved the impaired glucose tolerance.
|
| Animal Model: | db/db Mice | | Dosage: | 0.32~3.2 mg/kg | | Administration: | P.o. | | Result: | Dose-dependently reduced plasma glucose level.
|
| | IC 50 | PPAR-γ |
| | FK-614 Preparation Products And Raw materials |
|